Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation

被引：0
|
作者：
Sheldon M. Singh
Harindra C. Wijeysundera
机构：
[1] University of Toronto,Schulich Heart Centre, Sunnybrook Health Sciences Centre, Faculty of Medicine
[2] University of Toronto,Institute of Health Policy, Management and Evaluation
[3] Institute for Clinical Evaluative Sciences (ICES),undefined
来源：
Current Cardiology Reports | 2015年 / 17卷
关键词：
Anticoagulants; Atrial fibrillation; Cost-effectiveness analysis; Bleeding; Stroke;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Recently, novel oral anticoagulants (NOACs) have been approved for stroke prevention in patients with atrial fibrillation (AF). Although these agents overcome some disadvantages of warfarin, they are associated with increased costs. In this review, we will provide an overview of the cost-effectiveness of NOACs for stroke prevention in AF. Our comments and conclusions are limited to studies directly comparing all available NOACs within the same framework. The available cost-effectiveness analyses suggest that NOACs are cost-effective compared to warfarin, with apixaban likely being most favorable. However, significant limitations in these models are present and should be appreciated when interpreting their results.
引用
收藏
相关论文
共 50 条
  • [1] Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation
    Singh, Sheldon M.
    Wijeysundera, Harindra C.
    [J]. CURRENT CARDIOLOGY REPORTS, 2015, 17 (08)
  • [2] COST-EFFECTIVENESS OF NOVEL ORAL ANTICOAGULANTS FOR STROKE PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN CHINA
    Guo, W.
    Tian, X.
    Li, W.
    Han, S.
    [J]. VALUE IN HEALTH, 2018, 21 : S30 - S30
  • [3] Comparative cost-effectiveness of oral anticoagulants for stroke prevention in non-valvular atrial fibrillation patients in the UK
    Lip, G. Y. H.
    Lanitis, T.
    Kongnakorn, T.
    Phatak, H.
    Liu, L.
    Lawrence, J.
    Dorian, P.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 : 864 - 864
  • [4] COST-EFFECTIVENESS OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN COLOMBIA
    Garcia Pena, A. A.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A829 - A830
  • [5] Cost-effectiveness of Dabigatran for Stroke Prevention in Non-valvular Atrial Fibrillation in Spain
    Gonzalez-Juanatey, Jose R.
    Alvarez-Sabin, Jose
    Lobos, Jose M.
    Martinez-Rubio, Antoni
    Reverter, Joan C.
    Oyagueez, Itziar
    Gonzalez-Rojas, Nuria
    Becerra, Virginia
    [J]. REVISTA ESPANOLA DE CARDIOLOGIA, 2012, 65 (10): : 901 - 910
  • [6] Trials of Novel Oral Anticoagulants for Stroke Prevention In Patients with Non-valvular Atrial Fibrillation
    Halperin, Jonathan L.
    Dorian, Paul
    [J]. CURRENT CARDIOLOGY REVIEWS, 2014, 10 (04) : 297 - 302
  • [7] Cost-effectiveness of anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation in mainland China
    Zhou, Hui
    Nie, Xiaoning
    Jiang, Minghuan
    Dong, Weihua
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (04) : 523 - 530
  • [8] COST-EFFECTIVENESS OF DABIGATRAN FOR THE PREVENTION OF STROKE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN AUSTRALIA
    Tilden, D.
    Germanos, P.
    Gordon, J.
    Tocchini, L.
    Monz, B.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A375 - A375
  • [9] Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia
    Hersi, Ahmad S.
    Osenenko, Katherine M.
    Kherraf, Sid Ahmed
    Aziz, Ayman Abdel
    Sambrook, Robert Joseph
    [J]. ANNALS OF SAUDI MEDICINE, 2019, 39 (04) : 265 - 278
  • [10] Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a systematic and qualitative review
    Liberato, Nicola Lucio
    Marchetti, Monia
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2016, 16 (02) : 221 - 235
12345